Need pharma insights? Register for Evaluate Discovery

Learn More
Contact

Our Reports:

Precision Insights for Biotech Investing

From pipeline deep-dives to thematic research, our reports deliver the drug development intelligence you need to stay ahead.

Empowering confident investment decisions

Pharmalert delivers in-depth, structured deep-dive reports for institutional investors and concise, actionable briefs for retail investors. Our science-driven analysis cuts through complexity, offering unbiased insights into clinical trials, market dynamics, and competitive landscapes.

Pipeline

Deep-Dive Reports

Thematic

Research Reports

Regulatory

Intelligence Reports
Structured:

Pipeline Deep Dive Reports

Assessing the impact of key regulatory events—FDA approvals, clinical trial results, and more.

Key Features:

  • Drug Overview
  • Trial Rating
  • Market Profile
Structured:

Thematic Research Reports

Identifying emerging trends and investment opportunities in biotech and pharma.

Key Features:

  • Analysis of therapeutic areas (e.g., gene therapy, oncology).
  • Competitive landscape and market potential.
Structured:

Regulatory Intelligence Reports

Navigating the FDA and EMA regulatory landscape with confidence.

Key Features:

  • Approval pathway analysis.
  • Risk assessment and mitigation strategies.

What’s Inside a Brief?

Each Brief is structured around catalyst deep-dives, focusing on the most critical factors that could move a stock. Here’s what you’ll find:

Brief:

Quick, Actionable Insights for Retail Investors and Traders

Our Briefs are concise, focused reports designed for retail investors and traders who need quick, actionable insights into biotech and pharma companies. Unlike our in-depth reports, Briefs provide a streamlined analysis of key catalysts, risks, and opportunities, helping you make informed decisions without overwhelming detail.

Study Quality

FDA Interactions

Catalyst Focus

Risks and Opportunities

Guidance
  • Trial Design: Is the study well-designed? (e.g., randomized, double-blind, adequate sample size).
  • Endpoints: Are the primary and secondary endpoints meaningful and achievable?
  • Data Integrity: Are the results statistically significant and clinically relevant?
  • Regulatory History: How has the FDA responded so far? (e.g., Fast Track designation, CRLs, advisory committee feedback).
  • Key Concerns: Are there any red flags in the FDA’s communications?
  • Upcoming Milestones: What are the key catalysts? (e.g., Phase 3 results, PDUFA date, advisory committee meeting).
  • Timeline: When are these events expected?
  • Potential Impact: How could the stock react to positive or negative outcomes?
  • Risks: What could go wrong? (e.g., trial failure, regulatory delays, manufacturing issues).
  • Opportunities: What’s the upside? (e.g., market potential, competitive advantages).
  • Investment Takeaway: Clear, actionable recommendations tailored to retail investors and traders.
  • Positioning: How to approach the stock (e.g., buy, sell, hold, or trade around the catalyst).

Pharmalert’s Structured reports offer institutional investors a strategic edge in biotech investing by providing rigorous, data-driven analysis of emerging drug candidates. These reports go beyond surface-level coverage, delivering clinical trial assessments, regulatory insights, and competitivelandscape evaluations, helping investors identify high-potential assets before key catalysts.

With biotech mrkets driven by regulatory milestones and clinical data, access to early, well-researched intelligence can mean the difference between capitalizing on a breakthrough therapy or missing a major shift. Our reports offer a quantified risk-reward framework, integrating market potential, investment modeling, and company fundamentals, ensuring investors make timely, informed decisions in a high-stakes sector.

Request Sample Report

Why Choose Briefs?

Focused and Concise

Get the key insights you need without wading through lengthy reports.

Catalyst-Driven

Stay ahead of market-moving events with timely, actionable analysis.

Retail-Friendly

Designed specifically for retail investors and traders, with clear language and practical guidance.

Brief:

INP-105’s Path to FDA Approval

  • Study Quality:

    • Phase 3 trial design: Randomized, double-blind, 300 patients.
    • Primary endpoint: Reduction in agitation scores (p < 0.001).

  • Risks and Opportunities:

    • Risks: Manufacturing concerns, competitive landscape.
    • Opportunities: First in class potential, $1B market opportunity.

  • FDA Interactions:

    • Fast Track designation granted; no major concerns raised in pre-IND meeting.

  • Guidance:

    • Buy ahead of PDUFA date; set stop-loss at -20%.

  • Catalyst Focus:

    • Upcoming PDUFA date: December 15, 2023.
    • Potential stock impact: +50% on approval, -30% on rejection.

How to Access

  • Individual Reports:

    Purchase single reports tailored to your needs.

  • Monthly Subscription:

    Gain unlimited access to all reports for a flat monthly fee.

Ready to Gain the Edge in Biotech Investing?

Subscribe to our reports or request a custom analysis today.

Subscribe Now